Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2026)

Xeris Biopharma Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$8.8 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 181.7% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 363.01% YoY) and the FY2025 annual result came in at $11.4 million, down 68.51% from the prior year.
• Cash from Financing Activities was -$8.8 million for Q1 2026 at Xeris Biopharma Holdings, down from -$266000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $78.2 million in Q1 2022 and bottomed at -$8.8 million in Q1 2026.
• A 5-year average of $9.7 million and a median of $310000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 39224.8% in 2022, while the deepest fall reached 18800.0% in 2022.
• Xeris Biopharma Holdings' Cash from Financing Activities stood at $49.2 million in 2022, then plunged by 102.51% to -$1.2 million in 2023, then surged by 132.25% to $398000.0 in 2024, then sank by 166.83% to -$266000.0 in 2025, then sank by 3222.18% to -$8.8 million in 2026.
• Business Quant data shows XERS's Cash from Financing Activities at -$8.8 million in Q1 2026, -$266000.0 in Q4 2025, and $13.8 million in Q3 2025.